WILLIAM N. GIBBS, M.D.; WYCLIFFE S. LOFTERS, M.B.; MARIE CAMPBELL, M.D.; BARRIE HANCHARD, M.B.; LOIS LaGRENADE, M.B.; BEVERLEY CRANSTON, B.Sc; JAN HENDRIKS, M.Sc; ELAINE S. JAFFE, M.D.; CARL SAXINGER, Ph.D.; MARJORIE ROBERT-GUROFF, Ph.D.; ROBERT C. GALLO, M.D.; JEFFREY CLARK, M.D.; WILLIAM A. BLATTNER, M.D.
GIBBS WN, LOFTERS WS, CAMPBELL M, HANCHARD B, LaGRENADE L, CRANSTON B, et al. Non-Hodgkin Lymphoma in Jamaica and its Relation to Adult T-Cell Leukemia-Lymphoma. Ann Intern Med. 1987;106:361-368. doi: 10.7326/0003-4819-106-3-361
Download citation file:
Published: Ann Intern Med. 1987;106(3):361-368.
Of 95 patients consecutively diagnosed with non-Hodgkin lymphoma, 52 (55%) had antibodies to human T-cell leukemia-lymphoma virus, type I. Antibody positivity was strongly associated with skin involvement, leukemia, and hypercalcemia (p < 0.02). Two patients had systemic opportunistic infections. Neither meningeal nor lung infiltration was detected, and lymph node infiltration was diffuse in all patients. Of 36 patients who received immunophenotypic classifications, 30 had diseases that affected the T-cell system, and the cells of all tested patients with these diseases showed the helper/inducer (T4) phenotype. Twenty-seven of these thirty-six patients were found to have adult T-cell leukemia-lymphoma, and of the 27, 24 had antibodies to HTLV-I. The median duration of survival in patients with adult T-cell leukemia-lymphoma was 17 weeks, but a subgroup of 9 patients had indolent courses and a median survival of 81 weeks, which suggests that the disease has differing expression with courses that range from smoldering and indolent to acute and rapidly fatal. Hypercalcemia was the most important prognostic determinant of adult T-cell leukemia-lymphoma.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only